FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225482759> ?p ?o ?g. }

• W4225482759 abstract "Current guidelines recommend anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR Ab) as first-line treatment only in patients with left-sided RAS wild type (RASwt) metastatic colorectal cancer (mCRC). However, there are no guideline recommendations specific to tumor sidedness in subsequent-line treatment. This study aimed to investigate the effect of primary tumor location on second- or later-line treatment outcomes in patients with KRASwt mCRC.Medical records of patients diagnosed with mCRC at 3 academic centers in Thailand (Siriraj, Chulalongkorn, and Ramathibodi hospital) between 2008 and 2019 were retrospectively reviewed. Patients with KRASwt mCRC who received anti-EGFR Ab in second- or later-line treatment were included. The impact of tumor sidedness on progression-free survival (PFS) was determined using Kaplan-Meier method, and those results were compared using log-rank test.Among the 2,102 patients who had KRAS analysis data, 1,130 (54%) patients had KRASwt. Of those, 413 patients received anti-EGFR Ab in second- or later-line treatment. One hundred and sixty-two of 413 (39%) patients had extended RAS analysis. Seventy (17%) patients had right-sided tumors. Two hundred and thirty-eight (58%) patients received anti-EGFR Ab in the third line, and 132 (32%) patients and 43 (10%) patients were treated in the second and more than third line, respectively. Single-agent irinotecan was the most commonly used backbone chemotherapy (303/413, 73%). Patients with right-sided tumors had non-significantly inferior PFS compared to patients with left-sided tumors (median PFS: 5.7 months (mo), 95% confidence interval [CI]: 3.9-7.5 vs. 7.5 mo, 95% CI 6.5-8.5; p=0.17). Subgroup analysis showed no difference in PFS when stratified by treatment lines. Patient with right-sided tumors had significantly inferior OS compared to patients with left-sided tumors (median OS: 23.3 mo vs. 29.9 mo; p=0.005).To date, this is the largest real world data of the effect of primary tumor location on anti-EGFR Ab which demonstrated that tumor sidedness has no significant impact on treatment outcomes in KRASwt mCRC patients receiving second- or later-line therapy. Our findings do not support the utility of tumor sidedness for treatment selection in these settings. We confirmed that patients with right-sided tumors had significantly worse survival." @default.
• W4225482759 created "2022-05-05" @default.
• W4225482759 creator A5011730639 @default.
• W4225482759 creator A5017605521 @default.
• W4225482759 creator A5022564083 @default.
• W4225482759 creator A5022986629 @default.
• W4225482759 creator A5024541653 @default.
• W4225482759 creator A5044018634 @default.
• W4225482759 creator A5074046176 @default.
• W4225482759 creator A5079881949 @default.
• W4225482759 date "2022-02-15" @default.
• W4225482759 modified "2023-10-04" @default.
• W4225482759 title "Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study" @default.
• W4225482759 cites W1698245997 @default.
• W4225482759 cites W2005348280 @default.
• W4225482759 cites W2095201384 @default.
• W4225482759 cites W2098354753 @default.
• W4225482759 cites W2108235590 @default.
• W4225482759 cites W2111851685 @default.
• W4225482759 cites W2113029107 @default.
• W4225482759 cites W2123965006 @default.
• W4225482759 cites W2141163897 @default.
• W4225482759 cites W2147834058 @default.
• W4225482759 cites W242040007 @default.
• W4225482759 cites W2470575266 @default.
• W4225482759 cites W2520338075 @default.
• W4225482759 cites W2531140887 @default.
• W4225482759 cites W2543412381 @default.
• W4225482759 cites W2558788971 @default.
• W4225482759 cites W2605964154 @default.
• W4225482759 cites W2606920054 @default.
• W4225482759 cites W2609363527 @default.
• W4225482759 cites W2712978371 @default.
• W4225482759 cites W2774682757 @default.
• W4225482759 cites W2794202423 @default.
• W4225482759 cites W2795718561 @default.
• W4225482759 doi "https://doi.org/10.3389/fonc.2022.813009" @default.
• W4225482759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35242708" @default.
• W4225482759 hasPublicationYear "2022" @default.
• W4225482759 type Work @default.
• W4225482759 citedByCount "1" @default.
• W4225482759 countsByYear W42254827592023 @default.
• W4225482759 crossrefType "journal-article" @default.
• W4225482759 hasAuthorship W4225482759A5011730639 @default.
• W4225482759 hasAuthorship W4225482759A5017605521 @default.
• W4225482759 hasAuthorship W4225482759A5022564083 @default.
• W4225482759 hasAuthorship W4225482759A5022986629 @default.
• W4225482759 hasAuthorship W4225482759A5024541653 @default.
• W4225482759 hasAuthorship W4225482759A5044018634 @default.
• W4225482759 hasAuthorship W4225482759A5074046176 @default.
• W4225482759 hasAuthorship W4225482759A5079881949 @default.
• W4225482759 hasBestOaLocation W42254827591 @default.
• W4225482759 hasConcept C121608353 @default.
• W4225482759 hasConcept C126322002 @default.
• W4225482759 hasConcept C143998085 @default.
• W4225482759 hasConcept C167135981 @default.
• W4225482759 hasConcept C2776694085 @default.
• W4225482759 hasConcept C2777802072 @default.
• W4225482759 hasConcept C2778332735 @default.
• W4225482759 hasConcept C2779013556 @default.
• W4225482759 hasConcept C2779438470 @default.
• W4225482759 hasConcept C2779998722 @default.
• W4225482759 hasConcept C2780259306 @default.
• W4225482759 hasConcept C2780283643 @default.
• W4225482759 hasConcept C2780739268 @default.
• W4225482759 hasConcept C2781187634 @default.
• W4225482759 hasConcept C526805850 @default.
• W4225482759 hasConcept C71924100 @default.
• W4225482759 hasConceptScore W4225482759C121608353 @default.
• W4225482759 hasConceptScore W4225482759C126322002 @default.
• W4225482759 hasConceptScore W4225482759C143998085 @default.
• W4225482759 hasConceptScore W4225482759C167135981 @default.
• W4225482759 hasConceptScore W4225482759C2776694085 @default.
• W4225482759 hasConceptScore W4225482759C2777802072 @default.
• W4225482759 hasConceptScore W4225482759C2778332735 @default.
• W4225482759 hasConceptScore W4225482759C2779013556 @default.
• W4225482759 hasConceptScore W4225482759C2779438470 @default.
• W4225482759 hasConceptScore W4225482759C2779998722 @default.
• W4225482759 hasConceptScore W4225482759C2780259306 @default.
• W4225482759 hasConceptScore W4225482759C2780283643 @default.
• W4225482759 hasConceptScore W4225482759C2780739268 @default.
• W4225482759 hasConceptScore W4225482759C2781187634 @default.
• W4225482759 hasConceptScore W4225482759C526805850 @default.
• W4225482759 hasConceptScore W4225482759C71924100 @default.
• W4225482759 hasLocation W42254827591 @default.
• W4225482759 hasLocation W42254827592 @default.
• W4225482759 hasLocation W42254827593 @default.
• W4225482759 hasLocation W42254827594 @default.
• W4225482759 hasOpenAccess W4225482759 @default.
• W4225482759 hasPrimaryLocation W42254827591 @default.
• W4225482759 hasRelatedWork W2071471252 @default.
• W4225482759 hasRelatedWork W2165225928 @default.
• W4225482759 hasRelatedWork W2171311886 @default.
• W4225482759 hasRelatedWork W2617055067 @default.
• W4225482759 hasRelatedWork W2892376819 @default.
• W4225482759 hasRelatedWork W2913991184 @default.
• W4225482759 hasRelatedWork W3000288349 @default.
• W4225482759 hasRelatedWork W3147937635 @default.
• W4225482759 hasRelatedWork W349909140 @default.
• W4225482759 hasRelatedWork W4308954799 @default.

• next